Scientific article
Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers
ContributorsMercer, Louise K; Askling, Johan; Raaschou, Pauline; Dixon, William G; Dreyer, Lene; Hetland, Merete Lund; Strangfeld, Anja; Zink, Angela; Mariette, Xavier; Finckh, Axel
Published inAnnals of the Rheumatic Diseases, vol. 76, no. 2, p. 386-391
Publication date2017
Abstract
Keywords
- Abatacept/therapeutic use
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized/therapeutic use
- Antirheumatic Agents/therapeutic use
- Arthritis, Rheumatoid/drug therapy
- Biological Products/therapeutic use
- Europe/epidemiology
- Female
- Humans
- Incidence
- Male
- Melanoma/epidemiology
- Middle Aged
- Registries
- Risk Factors
- Rituximab/therapeutic use
- Skin Neoplasms/epidemiology
- Tumor Necrosis Factor-alpha/antagonists & inhibitors
Affiliation entities
Research groups
Citation (ISO format)
MERCER, Louise K et al. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. In: Annals of the Rheumatic Diseases, 2017, vol. 76, n° 2, p. 386–391. doi: 10.1136/annrheumdis-2016-209285
Main files (1)
Article (Published version)
Identifiers
- PID : unige:110911
- DOI : 10.1136/annrheumdis-2016-209285
- PMID : 27307502
Journal ISSN0003-4967
